DICERNA PHARMACEUTICALS INC's ticker is DRNA and the CUSIP is 253031108. A total of 85 filers reported holding DICERNA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $2,728,000 | -70.6% | 135,297 | -45.5% | 0.00% | -100.0% |
| Q2 2021 | $9,271,000 | +58.0% | 248,421 | +8.3% | 0.00% | 0.0% |
| Q1 2021 | $5,867,000 | +49.1% | 229,465 | +28.5% | 0.00% | 0.0% |
| Q4 2020 | $3,934,000 | -7.2% | 178,554 | -24.2% | 0.00% | 0.0% |
| Q3 2020 | $4,238,000 | -23.0% | 235,565 | +8.7% | 0.00% | 0.0% |
| Q2 2020 | $5,504,000 | +90.5% | 216,687 | +37.8% | 0.00% | 0.0% |
| Q1 2020 | $2,889,000 | +11.6% | 157,304 | +33.9% | 0.00% | – |
| Q4 2019 | $2,588,000 | -13.8% | 117,459 | -43.8% | 0.00% | – |
| Q3 2019 | $3,003,000 | +185.5% | 209,054 | +212.9% | 0.00% | – |
| Q2 2019 | $1,052,000 | -58.9% | 66,812 | -61.7% | 0.00% | – |
| Q1 2019 | $2,557,000 | +2162.8% | 174,561 | +1547.4% | 0.00% | – |
| Q4 2018 | $113,000 | -8.9% | 10,596 | +30.3% | 0.00% | – |
| Q3 2018 | $124,000 | +9.7% | 8,131 | -11.7% | 0.00% | – |
| Q2 2018 | $113,000 | +39.5% | 9,210 | +8.5% | 0.00% | – |
| Q1 2018 | $81,000 | – | 8,491 | +24160.0% | 0.00% | – |
| Q4 2017 | $0 | -100.0% | 35 | -91.2% | 0.00% | – |
| Q3 2017 | $2,000 | – | 397 | +1034.3% | 0.00% | – |
| Q2 2017 | $0 | – | 35 | 0.0% | 0.00% | – |
| Q1 2017 | $0 | -100.0% | 35 | -96.8% | 0.00% | – |
| Q4 2016 | $3,000 | +200.0% | 1,095 | +491.9% | 0.00% | – |
| Q3 2016 | $1,000 | -95.5% | 185 | -97.5% | 0.00% | – |
| Q2 2016 | $22,000 | +100.0% | 7,326 | +279.6% | 0.00% | – |
| Q1 2016 | $11,000 | -75.6% | 1,930 | -49.2% | 0.00% | – |
| Q4 2015 | $45,000 | +2150.0% | 3,800 | +1643.1% | 0.00% | – |
| Q3 2015 | $2,000 | -77.8% | 218 | -65.0% | 0.00% | – |
| Q2 2015 | $9,000 | +125.0% | 623 | +256.0% | 0.00% | – |
| Q1 2015 | $4,000 | -92.0% | 175 | -94.2% | 0.00% | – |
| Q4 2014 | $50,000 | -66.9% | 3,030 | -74.5% | 0.00% | – |
| Q3 2014 | $151,000 | +88.8% | 11,900 | +235.7% | 0.00% | – |
| Q2 2014 | $80,000 | -43.3% | 3,545 | -29.1% | 0.00% | – |
| Q1 2014 | $141,000 | – | 5,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 1,355,392 | $29,859,000 | 6.21% |
| Bain Capital Life Sciences Investors, LLC | 3,080,237 | $67,858,000 | 4.26% |
| DAFNA Capital Management LLC | 587,756 | $12,948,000 | 3.85% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 227,388 | $5,009,000 | 2.91% |
| RTW INVESTMENTS, LP | 7,253,857 | $159,802,000 | 2.68% |
| Parkman Healthcare Partners LLC | 331,513 | $7,303,000 | 1.87% |
| Evolutionary Tree Capital Management, LLC | 60,864 | $1,341,000 | 1.02% |
| Eagle Health Investments LP | 69,000 | $1,520,000 | 0.97% |
| Woodline Partners LP | 1,358,796 | $29,934,000 | 0.79% |
| Affinity Asset Advisors, LLC | 40,000 | $881,000 | 0.47% |